Lexeo Therapeutics (LXEO) executive compensation, 2026 proxy

R. Nolan Townsend, Chief Executive Officer and Director, was paid $3.7M in 2025, down 17% from $4.4M the year before.

Filed
April 30, 2026
Annual meeting
June 25, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.7M-17% vs prior year
CEO pay in equity
73%$2.7M in awards
CFO total compensation
$1,665,915Joined August 2025
Former CLO total compensation
$2,145,883Resigned December 31, 2025
Robertson all other compensation
$609,386Included separation-related amounts
Townsend target bonus
55%Of annual base salary
Tamayo target bonus
40%Of annual base salary
Robertson lump-sum payment
$229,800Under transition agreement

How Townsend was paid

$3.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary17%Stock awards41%Option awards32%Non-equity incentive10%All other compensation0%

Named executive officers

ExecutiveTotal
R. Nolan TownsendChief Executive Officer and Director$3,650,940
Louis TamayoChief Financial Officer$1,665,915
Jenny R. Robertson, J.D.Former Chief Legal Officer$2,145,883

What changed and why

  • $3.7M2025 CEO total compensation was $3,650,940, compared with $4,375,248 in 2024.
  • $633K2025 CEO salary was $632,700, while non-equity incentive compensation was $347,985.
  • $1.5M2025 CEO stock and option awards totaled $1,493,488 and $1,165,982, respectively.
  • $1.7MLouis Tamayo joined in August 2025 and received total compensation of $1,665,915.
  • $609KJenny Robertson’s $609,386 in all other compensation included separation-related equity modifications and COBRA premiums.
  • 55%Townsend’s 2026 annual target bonus is 55% of base salary; Tamayo’s is 40%.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.